Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06531733 · ClinicalTrials.gov registry record · NA

Artemis Sleep Countermeasures

A NA study of Fatigue, sponsored by National Aeronautics and Space Administration (NASA).

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT06531733: Recruiting NA study of Fatigue, sponsored by National Aeronautics and Space Administration (NASA).

NCT06531733 is a NA study of Fatigue that is actively recruiting participants, run by National Aeronautics and Space Administration (NASA). The registered enrollment target is 24 participants, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06531733, a NA study of Fatigue, is actively recruiting participants, sponsored by National Aeronautics and Space Administration (NASA).

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Purpose. The purpose of this study is to test sleep and wake-promoting countermeasures to evaluate their effectiveness in helping individuals fall asleep quickly, maintain sleep during a nap, and maintain alertness during waking. Protocol Overview. The proposed study involves two laboratory visits separated by at least one week. Participants are required to complete all procedures in the companion screening and at-home protocol in order to qualify for this laboratory protocol. The at-home protocol involves keeping a regular schedule for 2-3 weeks. Participants will need to maintain a regular schedule with at least 8.5 hours in bed for at least one week prior to the first laboratory visit. They will then continue the at-home protocol, maintaining at least 8.5 hours in bed each night for at least a week before completing the second laboratory visit. There are two interventions that participants will experience during the study, sleep promoting (pink noise) and wake promoting (blue enriched lighting plus a nap). These will be delivered separately and together depending on randomization. Participants will first be randomized to one of three conditions sleep promoting + wake placebo, sleep placebo + wake promoting, or sleep promoting + wake promoting. All participants will complete a sleep placebo + wake placebo condition. The order of the full placebo condition versus the intervention (i.e., lab visit 1 vs. lab visit 2) will be randomized after the condition randomization occurs. Each participant will complete one of the interventions and one placebo for a total of two visits.

Conditions Studied

Interventions

  • DEVICE Sleep Promoting (pink noise)
  • DEVICE Wake Promoting (blue enriched light plus a nap)

Study Locations (1)

California

  • NASA Ames Research Center - Mountain View

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-06-22
Est. Completion 2025-06-01
Phase NA

What NCT06531733 shows while recruiting

NCT06531733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Fatigue appearing as the primary indexed condition, and to 2 interventions - of which Sleep Promoting (pink noise) is the first listed.

NCT06531733 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06531733 about?

NCT06531733 is a clinical study titled "Artemis Sleep Countermeasures". Purpose. The purpose of this study is to test sleep and wake-promoting countermeasures to evaluate their effectiveness in helping individuals fall asleep quickly, maintain sleep during a nap, and maintain alertness during waking. Protocol Overview. The proposed study involves two laboratory visits ...

What is the current status of trial NCT06531733?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2024-06-22. Estimated completion is 2025-06-01.

What conditions does trial NCT06531733 study?

This clinical trial studies the following conditions: Fatigue.

What interventions are being tested in trial NCT06531733?

The interventions under investigation include: Sleep Promoting (pink noise) (DEVICE), Wake Promoting (blue enriched light plus a nap) (DEVICE).

Who is sponsoring clinical trial NCT06531733?

This trial is sponsored by National Aeronautics and Space Administration (NASA), which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06531733 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fatigue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06531733's enrollment target sits among peer trials

24 91st of 109 higher than 16 of 109 other Fatigue trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fatigue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06531733, the US trial registry maintained by the National Library of Medicine. NCT06531733 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.